Evaluation of Immunocompetent Urinary Tract Infected Balb/C Mouse Model For the Study of Antibiotic Resistance Development Using Escherichia Coli CFT073 Infection

Abstract

Urinary tract infections (UTI) are common worldwide and are becoming increasingly difficult to treat because of the development of antibiotic resistance. Immunocompetent murine models of human UTI have been used to study pathogenesis and treatment but not for investigating resistance development after treatment with antibiotics. In this study, intravesical inoculation of uropathogenic Escherichia coli CFT073 in immunocompetent Balb/c mice was used as a model of human UTI. The value of the model in investigating antibiotic exposure on in vivo emergence of antibiotic resistance was examined. Experimentally infected mice were treated with 20 or 200 mg/kg ampicillin, 5 or 50 mg/kg ciprofloxacin, or 100 or 1000 mg/kg of fosfomycin. Ampicillin and ciprofloxacin were given twice daily at 8 h intervals, and fosfomycin was given once daily. Antibiotic treatment began 24 h after bacterial inoculation and ended after 72 h following the initial treatment. Although minimum inhibitory concentrations (MIC) for the experimental strain of E. coli were exceeded at peak concentrations in tissues and consistently in urine, low levels of bacteria persisted in tissues in all experiments. E. coli from bladder tissue, kidney, and urine grew on plates containing 1× MIC of antibiotic, but none grew at 3× MIC. This model is not suitable for studying emergent resistance but might serve to examine bacterial persistence.

FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens

“…Urinary tract infections (UTIs) caused by different microbial agents, including both Gram-positive and Gram-negative bacteria and fungi, are among the most prevalent infectious diseases affecting millions of people annually [ 1 , 2 , 3 , 4 , 5 , 6 ]. Most UTIs are community- and nosocomial-acquired infections, which can occur in any part of the urinary tract [ 4 , 6 , 7 , 8 , 9 , 10 ].…”

The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice

“…The initial objectives of the work include tracking the evolution of resistance of the pathogens in the bladder and characterizing the similarities and differences in influence of antibiotics with differing mechanisms of action on the gut resistome and community composition. While work about the first objective was published elsewhere [38], this manuscript reports findings about the second objective and characterizes the changes in the gut microbiome. The initial endpoints of characterization were shifts in gut microbial community and changes in relative abundance of recognized antibiotic resistance genes, or identification of emergent antimicrobial-resistant genes.…”

Anthocran® Phytosome®: Prevention of Recurring Urinary Infections and Symptoms after Catheterization

“…Nevertheless, the use of lecithin as emulsifier, stabilizer, dispersing aid, and release agent is acknowledged as the molecule is recognized as a safe and inactive compound (35). Lecithin has been used as excipient in a study evaluating the antibiotic resistance to urinary infections in mice, with no specific reports of involvement in any mechanism but the generation of an oral dispersion to favor administration (36). In addition, in human patients, lecithin has been tested as a coating agent for catheter and its presence has not reported to be associated to any specific effect (37).…”